Pharma giant GlaxoSmithKline (GSK) submitted its latest treatment for type two diabetes to the US Food and Drug Administration (FDA) for regulatory approval.
The firm said albiglutide BLA, an investigational once-weekly treatment for adult patients, was not yet approved as a treatment for type two diabetes or any other indication anywhere in the world.
GSK intends to submit a regulatory application in the European Union in early 2013.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE
Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
At 1030 the company's share were down 0.65% at 1,373.5p.
MM
-
8 of the best houses for sale with annexesThe best houses with annexes – from a period property in the Lake District to a 13th-century house with a two-bedroom annexe in Saltwood, Kent
-
Zelenskyy moves to appease Donald Trump – what happens now?Ukraine’s president Volodymyr Zelenskyy is conceding ground to secure the least-worst deal possible, says Emily Hohler
